Form 4: Fate Therapeutics CEO Awarded Significant Equity

Fate Therapeutics' President and CEO, Bahram Valamehr, received an award of 335,000 restricted stock units and 1,300,000 stock options.

Summary

• Bahram Valamehr, President and CEO of FATE THERAPEUTICS INC, was awarded 335,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 15, 2026.
• The RSUs will vest in four equal annual installments, with 1/4th vesting on January 8, 2027, January 8, 2028, January 8, 2029, and January 8, 2030, contingent on continued service.
• Mr. Valamehr also received an award of 1,300,000 stock options on January 15, 2026, with an exercise price of $1.05 per share.
• These stock options will vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, subject to continued service.
• Following these transactions, Mr. Valamehr beneficially owns 664,708 shares of common stock directly and 1,300,000 stock options directly.
• The filing indicates these transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as significant equity awards align management's interests with shareholders and incentivize long-term performance. This is a standard and expected form of executive compensation, reflecting confidence in the executive's continued leadership.

Positives

• The significant equity awards align the interests of the President and CEO with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options promote retention of key executive talent over several years.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate an expectation of continued service from the President and CEO, Bahram Valamehr, through at least January 2030 for RSUs and January 2029 for stock options. This suggests a commitment to long-term leadership and strategic execution.

Industry Context

Executive compensation in the biotechnology industry frequently includes substantial equity components like RSUs and stock options. This practice is designed to align executive incentives with shareholder value creation, particularly given the long development cycles and high-risk, high-reward nature of drug discovery and commercialization. The size of the award is typical for a CEO of a publicly traded biotech company, reflecting the competitive landscape for executive talent.

Comparison to Industry Standards

• The structure of these equity awards, combining Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules, is a standard practice in executive compensation across the biotechnology and broader technology sectors.
• The use of a Rule 10b5-1(c) plan for these transactions is a common mechanism for insiders to manage their equity holdings in compliance with insider trading regulations, demonstrating adherence to corporate governance best practices.
• While specific comparable companies or projects are not detailed in this filing, similar compensation packages are observed for CEOs at peer biotech firms of comparable market capitalization and development stage, aiming to attract and retain top leadership in a highly competitive talent market.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the CEO's financial interests with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: Executive compensation practices can influence overall company morale and compensation strategies, though this filing specifically addresses the CEO's awards.

Next Steps

• The company will continue to monitor the vesting of the awarded Restricted Stock Units on January 8, 2027, January 8, 2028, January 8, 2029, and January 8, 2030.
• The company will track the monthly vesting of the stock options, leading to full vesting on January 1, 2029.

Key Dates

Keywords

FATE, Fate Therapeutics, Bahram Valamehr, Restricted Stock Units, RSU, Stock Options, Equity Award, CEO Compensation, Insider Transaction, Form 4, Executive Compensation